Patents Assigned to The University of Virginia
-
Publication number: 20240136040Abstract: A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.Type: ApplicationFiled: December 20, 2023Publication date: April 25, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATINInventors: Boris P. KOVATCHEV, Stephen D. PATEK, Marc D. BRETON
-
Patent number: 11965810Abstract: An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.Type: GrantFiled: September 26, 2019Date of Patent: April 23, 2024Assignee: University of Virginia Patent FoundationInventors: Nathan Swami, John McGrath, Walter Varhue, Carlos Honrado, Vahid Farmehini, Yi Liu
-
Publication number: 20240127967Abstract: Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.Type: ApplicationFiled: February 9, 2022Publication date: April 18, 2024Applicants: University of Virginia Patent Foundation, Fred Hutchinson Cancer Research CenterInventors: Judith M. White, Shuang Xu, Joshua T. Schiffer, Gene G. Olinger, Courtney L. Finch, Julie Dyall, Stephen J. Polyak, Lisa Johansen
-
Patent number: 11957682Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: June 27, 2022Date of Patent: April 16, 2024Assignee: University of Virginia Patent FoundationInventors: Hui Li, Zhongqiu Xie
-
Patent number: 11957664Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.Type: GrantFiled: March 23, 2023Date of Patent: April 16, 2024Assignee: University of Virginia Patent FoundationInventor: Bankole A. Johnson
-
Publication number: 20240121620Abstract: Embodiments relate to a dynamic spectrum access (DSA) system including a DSA transmitter configured to generate a complex signal for a secondary communication system, the complex signal being within a communication band A that is equal to or falls within a communication band B of a primary communication system. The complex signal includes a first signal and a second signal that is a repeat of the first signal. The power of the complex signal received at the secondary communication receiver is greater than the noise floor of the secondary communication system, but is equal to or less than the interference power from the primary communication. The DSA system includes a DSA receiver including a plurality of DSA antennas and a DSA signal processing module, the DSA signal processing module configured to perform canonical correlation analysis (CCA) on the complex signal.Type: ApplicationFiled: December 10, 2021Publication date: April 11, 2024Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Mohamed Salaheldeen IBRAHIM, Nikolaos Dimitrios Sidiropoulos
-
Publication number: 20240115729Abstract: Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.Type: ApplicationFiled: February 4, 2022Publication date: April 11, 2024Applicant: University of Virginia Patent FoundationInventors: Kimberly A. Kelly, Ph.D., Jessica Hung
-
Publication number: 20240117358Abstract: Provided herein is a previously unannotated IncRNA lying within exon six and 3?UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCK gene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.Type: ApplicationFiled: October 16, 2023Publication date: April 11, 2024Applicant: University of Virginia Patent FoundationInventor: Daniel G. Gioeli
-
Patent number: 11950935Abstract: A system for generating a hypoglycemia risk signal associated with exercise-induced Hypoglycemia. The system can include a processor configured to obtain a blood glucose signal (BGstart), a ratio of absolute insulin on board over total daily insulin signal (IOBabs/TDI), and an initial glycemic slope signal (S0); generate a hypoglycemia risk signal based on a hypoglycemia prediction algorithm that determines the probability of a user being hypoglycemic during or after exercise based on the obtained BGstart, IOBabs/TDI and S0.Type: GrantFiled: February 8, 2023Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Marc D. Breton, Najib Ben-Brahim
-
Patent number: 11951303Abstract: The epicardial pacing system and related method includes an epicardial catheter configured to be disposed in the middle mediastinum of the thorax of a subject for use in electrical pacing of the heart at one or more locations on the epicardial surface. The epicardial pacing catheter may include at least one electrode whereby the electrode is insulated on at least one side to allow pacing of the heart without damage to adjacent anatomical structures.Type: GrantFiled: April 23, 2018Date of Patent: April 9, 2024Assignee: University of Virginia Patent FoundationInventors: Srijoy Mahapatra, George T. Gillies
-
Patent number: 11954578Abstract: Systems and methods for denoising a magnetic resonance (MR) image utilize an unsupervised deep convolutional neural network (U-DCNN). Magnetic resonance (MR) image data of an area of interest of a subject can be acquired, which can include noisy input images that comprise noise data and noise free image data. For each of the noisy input images, iterations can be run of a converging sequence in an unsupervised deep convolutional neural network. In each iteration, parameter settings are updated; the parameter settings are used in calculating a series of image feature sets with the U-DCNN. The image feature sets predict an output image. The converging sequence of the U-DCNN is terminated before the feature sets predict a respective output image that replicates all of the noise data from the noisy input image. Based on a selected feature set, a denoised MR image of the area of interest of the subject can be output.Type: GrantFiled: April 24, 2020Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Craig H Meyer, Xue Feng
-
Patent number: 11951278Abstract: An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.Type: GrantFiled: March 15, 2022Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Marc D. Breton, Stephen D. Patek, Boris P. Kovatchev
-
Patent number: 11950877Abstract: A computerized system and method of modeling myocardial tissue perfusion can include acquiring a plurality of original frames of magnetic resonance imaging (MRI) data representing images of a heart of a subject and developing a manually segmented set of ground truth frames from the original frames. Applying training augmentation techniques to a training set of the originals frame of MRI data can prepare the data for training at least one convolutional neural network (CNN). The CNN can segment the training set of frames according to the ground truth frames. Applying the respective input test frames to a trained CNN can allow for segmenting an endocardium layer and an epicardium layer within the respective images of the input test frames. The segmented images can be used in calculating myocardial blood flow into the myocardium from segmented images of the input test frames.Type: GrantFiled: February 5, 2020Date of Patent: April 9, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Craig H. Meyer, Xue Feng, Michael Salerno
-
Patent number: 11944665Abstract: In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease comprise by increasing flow via meningeal lymphatic vessels are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of inflammatory neurological disease be inhibiting or preventing immune cell migration through meningeal lymphatic vessels are described.Type: GrantFiled: May 31, 2017Date of Patent: April 2, 2024Assignee: University of Virginia Patent FoundationInventors: Jonathan Kipnis, Antoine Louveau, Sandro Da Mesquita
-
Patent number: 11945825Abstract: The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.Type: GrantFiled: July 1, 2021Date of Patent: April 2, 2024Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Kyle Hoehn, Brandon Kenwood
-
Publication number: 20240100081Abstract: It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-? (IFN-?) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-?, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness.Type: ApplicationFiled: May 12, 2023Publication date: March 28, 2024Applicant: University of Virginia Patent FoundationInventors: Jayakrishna Ambati, Nagaraj Kerur
-
Patent number: 11937848Abstract: A method and apparatus for performing electrocautery on a site of a subject that includes inserting a trocar device into the location of the site of the subject and electro-cauterizing the site of the subject using a diode included with the trocar device. A method and apparatus for performing electrocautery on a site of a subject that includes inserting one or more medical tubes or medical instruments or devices that extends through an expandable sheath; and electro-cauterizing the site of the subject using a diode included with the expandable sheath device.Type: GrantFiled: June 9, 2017Date of Patent: March 26, 2024Assignee: University of Virginia Patent FoundationInventors: Gorav Ailawadi, James Hunter Mehaffey
-
Patent number: 11937872Abstract: An aspect of various embodiments of the present invention system and method provide, but not limited thereto, a novel means for epicardial ablation using a double-curve steerable sheath and a double-curve deflectable open irrigated-tip/suction catheter that can be guided around the apex of the heart and adjusted so as to position the distal tip optimally. The catheter can also both deliver fluid to and withdraw fluid from the pericardial space. Access to the epicardial surface of the heart is via a subxiphoid entry. The method and means presented include, but are not limited to, steering, energy delivery, bipolar mapping, placement and use of electrodes, irrigation, suction of irrigation fluid, and other details of the subject invention.Type: GrantFiled: December 31, 2018Date of Patent: March 26, 2024Assignee: University of Virginia Patent FoundationInventors: Srijoy Mahapatra, George T. Gillies
-
Patent number: 11931352Abstract: This invention relates to methods and compositions for treatment of inv (16) leukemia and particularly to treatment of acute myeloid leukemia. Disclosed is a method of treating inv (16) leukemia comprising the step of administering to a subject in in need thereof a therapeutically effective combination of a) a compound of the formula (1) (1) and b) a BRD4 inhibitor selected from the group consisting of JQ1, CeMMECZ, 1-BET 151 (or GSK1210151A), 1-BET 762 (or GSK525762), PFI-1, bromosporine, OTX-015 (or MK-8628), TEN-010, CPI-203, CPI-0610, RVX-208, BI2536, TG101348, LY294002, ABBV-075 (or mivebresib), FT-1101, ZEN003694, pharmaceutically acceptable salts and mixtures thereof. The therapeutically effective combination synergistically inhibits proliferation of inv (16) leukemia cells. This invention also relates to pharmaceutical compositions comprising a therapeutically effective combination of the compound of formula (1) and the BRD4 inhibitor and a pharmaceutically acceptable excipient.Type: GrantFiled: May 24, 2019Date of Patent: March 19, 2024Assignees: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, UNIVERSITY OF MASSACHUSETTSInventors: John H. Bushweller, Anuradha Illendula, Lucio Hernan Castilla, John Anto Pulikkan
-
Publication number: 20240081300Abstract: Provided are compositions and methods for treating and/or preventing seizure-induced death in subjects in need thereof. In some embodiments, the methods include methods for inducing an audiogenic seizure and/or seizure-induced death, treating and/or preventing death associated with seizures in subjects, preventing sudden unexpected death in epilepsy (SUDEP) in subjects, preventing and/or reducing the risk of death in subjects having SCN8A gain-of-function mutations, preventing or reducing the risk of death associated with tonic seizures in subjects, and preventing or reducing the risk of death associated with epileptic seizures in subjects. Also provided are animals that have been modified to carry gain-of-function SCN8A mutations and methods for using the same to identify compounds that have activity in treating and/or preventing seizures and/or seizure-induced death in subjects.Type: ApplicationFiled: January 12, 2022Publication date: March 14, 2024Applicant: University of Virginia Patent FoundationInventors: Manoj K. Patel, Ian C. Wenker, Eric R. Wengert